�鶹��ý

Mary Hendrickson draws on her years of in-house experience to help clients navigate regulatory laws and compliance programs, as well as transactional matters. She knows how to balance the demands of business and law to reduce risk and develop creative solutions to complex issues. In addition to being an attorney, Mary is a Pharm.D. and has practiced pharmacy in multiple practice settings.

Mary has extensive experience advising pharmacies and health care entities, including health care systems and providers, wholesale distributors, reverse pharmaceutical distributors, pharmaceutical manufacturers, and pharmacy benefits managers (PBMs) on regulatory, transactional, and compliance program matters. She advises companies on regulatory compliance matters involving state pharmacy boards, the U.S. Food and Drug Administration (FDA), the U.S. Environmental Protection Agency (EPA), the U.S. Drug Enforcement Administration (DEA), Medicare Part D, and 340B programs, as well as related health care regulations. In addition, she has specific clinical trial experience, having overseen an office of clinical research and innovative care compliance at a large academic health system, as well as compliance oversight of clinical trial logistics at a large wholesale distributor.

She has in-depth experience evaluating, restructuring, and advancing compliance programs of all sizes and advising executive management and board members on compliance matters, including the audit committee’s responsibility associated with compliance program oversight and enterprise risk management (ERM) programs. Mary is adept at guiding companies through these many risks and challenges to achieve a positive outcome.

In addition, Mary has extensive experience working in the health care and pharmaceutical supply chain, including with wholesale distributors, third-party logistics (3PLs), and reverse pharmaceutical distributors. Her experience includes advising all types of entities that intersect with EPA, FDA, DEA, and other health care regulators to minimize risk in managing not only the forward movement of product in the supply chain, but also the return of product or disposition of hazardous, pharmaceutical, infectious, medical, and controlled substance waste.

Before joining �鶹��ý, Mary served on the leadership teams at companies of various sizes, including Fortune 10 companies. In these roles she distilled complex regulatory and compliance concepts to inform and lead business solutions, reduce risk, and increase operational efficiency. Throughout her career, she has been a trusted advisor to executive teams, board members, management, and staff in both private and publicly held companies.